Dr. Myles Greenberg has more than 20 years’ experience in growing healthcare, medical technology and life sciences firms as an entrepreneur, operating executive, board member, clinician and investor. Prior to joining Alucent, he served as Chief Development Officer at IntegraMed America, a private equity backed healthcare services firm. He still serves today on the Board of Directors at Urgent Care Centers of New England, a company he co-founded.
Dr. Greenberg has spent most of his career as an early-stage venture capital investor with CHL Medical Partners, HealthInvest Equity Partners, and Pappas Ventures. Dr. Greenberg served as a board member, lead director, and in interim management roles in numerous biotech, medical device, and healthcare services firm. Eight of the companies where Dr. Greenberg played a major investor and advisory role were acquired or went public.
Dr. Greenberg began his career as a faculty physician and hospital administrator at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston. He holds a Master of Business Administration from Harvard Business School, Doctor of Medicine from Yale University School of Medicine, and a Bachelor of Applied Science from the University of Pennsylvania. He is a Diplomate of the American Board of Emergency Medicine.
As an entrepreneur, venture capitalist and former practicing physician, Steve knows firsthand the challenges of building successful healthcare companies. Unfazed by complexity in healthcare, whether technical, regulatory, or market driven, Steve's mission has been to make healthcare delivery more effective and affordable.
Before co-founding EvolveImmune, Steve helped start and finance leading healthcare companies as a general partner at Canaan Partners. Steve currently serves on the boards of companies in biopharma (Liquidia (LQDA – NASDAQ, board chairman), digital health (Truveris, Ambra Health, Corvium and Genome Medical), and medical devices (Onkos Surgical). Past board roles include Amicus Therapeutics (FOLD-NASDAQ), Marinus Pharmaceuticals (MRNS-NASDAQ) and Advanced BioHealing (M&A with Shire). Steve is a member of Dartmouth Medical School’s Board of Advisors.
Before joining Canaan in 2002, Steve helped found and manage multiple start-ups, including Radiology Management Sciences (RMS) where he was CEO for 6 years, OmniSonics and TeleRad. Previously, Steve was a strategic pharmaceutical consultant for Arthur D. Little. Steve was an Ewing Marion Kauffman Fellow, an educational program to develop future leaders in venture capital.
Steve obtained his AB from Dartmouth College, a MA in the history of science from Harvard, and his medical degree from the University of Rochester. Steve completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).